A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

NCT04147819 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancers With HER2 Expression

Interventions

DRUG: BAY2701439
DRUG: BAY2701439

Sponsor

Bayer